| Literature DB >> 34969370 |
Lijun Gan1, Dandan Sun1, Yuntao Cheng2, Deyang Wang2, Fen Wang1, Lin Wang3, Wei Li4, Dandan Shen2, Daotong Guo2, Zonglei Zhang2, Haiyan Wang2, Jinli Li2, Yong Yang2, Tao Liang5.
Abstract
BACKGROUND: There is no clear evidence for the target value of blood pressure control after Percutaneous coronary intervention (PCI). Therefore, our study was designed to explore the relationship between blood pressure after PCI and major adverse cardiac events (MACE) during 3-year follow-up.Entities:
Mesh:
Year: 2021 PMID: 34969370 PMCID: PMC8717657 DOI: 10.1186/s12872-021-02435-2
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Inclusion/exclusion criteria of the patients
Baseline characteristics of participants
| Blood pressure tertiles (mmHg) | SBP | DBP | ||||||
|---|---|---|---|---|---|---|---|---|
| Low | Middle | High | P value* | Low | Middle | High | P value* | |
| 171 | 171 | 172 | 171 | 170 | 173 | |||
| Age | 61.82 ± 10.34 | 60.44 ± 9.66 | 63.50 ± 8.16 | 0.022 | 64.14 ± 10.05 | 61.26 ± 9.50 | 60.39 ± 8.52 | < 0.001 |
| 0.002 | 0.852 | |||||||
| Male | 126 (73.68%) | 121 (70.76%) | 98 (56.98%) | 112 (65.50%) | 116 (68.24%) | 117 (67.63%) | ||
| Female | 45 (26.32%) | 50 (29.24%) | 74 (43.02%) | 59 (34.50%) | 54 (31.76%) | 56 (32.37%) | ||
| 0.350 | 0.221 | |||||||
| Nondrinker | 105 (61.40%) | 100 (58.48%) | 113 (65.70%) | 116 (67.84%) | 104 (61.18%) | 98 (56.65%) | ||
| Current drinker | 51 (29.82%) | 62 (36.26%) | 48 (27.91%) | 45 (26.32%) | 52 (30.59%) | 64 (36.99%) | ||
| Quit | 15 (8.77%) | 9 (5.26%) | 11 (6.40%) | 10 (5.85%) | 14 (8.24%) | 11 (6.36%) | ||
| 0.288 | 0.718 | |||||||
| Nonsmoker | 82 (47.95%) | 83 (48.54%) | 97 (56.40%) | 88 (51.46%) | 83 (48.82%) | 91 (52.60%) | ||
| Current smoker | 53 (30.99%) | 61 (35.67%) | 48 (27.91%) | 53 (30.99%) | 60 (35.29%) | 49 (28.32%) | ||
| Quit | 36 (21.05%) | 27 (15.79%) | 27 (15.70%) | 30 (17.54%) | 27 (15.88%) | 33 (19.08%) | ||
| 0.032 | 0.697 | |||||||
| Illiterate | 29 (16.96%) | 38 (22.22%) | 52 (30.23%) | 43 (25.15%) | 37 (21.76%) | 39 (22.54%) | ||
| Primary school | 45 (26.32%) | 34 (19.88%) | 45 (26.16%) | 46 (26.90%) | 40 (23.53%) | 38 (21.97%) | ||
| Junior school | 52 (30.41%) | 56 (32.75%) | 36 (20.93%) | 48 (28.07%) | 48 (28.24%) | 48 (27.75%) | ||
| High school and above | 45 (26.32%) | 43 (25.15%) | 39 (22.67%) | 34 (19.88%) | 45 (26.47%) | 48 (27.75%) | ||
| 0.659 | 0.470 | |||||||
| No | 165 (96.49%) | 167 (97.66%) | 165 (95.93%) | 167 (97.66%) | 165 (97.06%) | 165 (95.38%) | ||
| Yes | 6 (3.51%) | 4 (2.34%) | 7 (4.07%) | 4 (2.34%) | 5 (2.94%) | 8 (4.62%) | ||
| 0.876 | 0.766 | |||||||
| No | 125 (73.10%) | 121 (70.76%) | 125 (72.67%) | 120 (70.18%) | 125 (73.53%) | 126 (72.83%) | ||
| Yes | 46 (26.90%) | 50 (29.24%) | 47 (27.33%) | 51 (29.82%) | 45 (26.47%) | 47 (27.17%) | ||
| 0.239 | 0.332 | |||||||
| No | 166 (97.08%) | 170 (99.42%) | 170 (98.84%) | 168 (98.25%) | 166 (97.65%) | 172 (99.42%) | ||
| Yes | 5 (2.92%) | 1 (0.58%) | 2 (1.16%) | 3 (1.75%) | 4 (2.35%) | 1 (0.58%) | ||
| < 0.001 | < 0.001 | |||||||
| No | 108 (63.16%) | 65 (38.01%) | 35 (20.35%) | 94 (54.97%) | 60 (35.29%) | 54 (31.21%) | ||
| Yes | 63 (36.84%) | 106 (61.99%) | 137 (79.65%) | 77 (45.03%) | 110 (64.71%) | 119 (68.79%) | ||
| < 0.001 | < 0.001 | |||||||
| No | 63 (36.84%) | 106 (61.99%) | 137 (79.65%) | 77 (45.03%) | 110 (64.71%) | 119 (68.79%) | ||
| Yes | 108 (63.16%) | 65 (38.01%) | 35 (20.35%) | 94 (54.97%) | 60 (35.29%) | 54 (31.21%) | ||
| 0.398 | 0.124 | |||||||
| No | 161 (94.15%) | 163 (95.32%) | 157 (91.28%) | 159 (92.98%) | 155 (91.18%) | 167 (96.53%) | ||
| Yes | 10 (5.85%) | 8 (4.68%) | 15 (8.72%) | 12 (7.02%) | 15 (8.82%) | 6 (3.47%) | ||
| 0.002 | 0.065 | |||||||
| No | 153 (89.47%) | 149 (87.13%) | 132 (76.74%) | 152 (88.89%) | 144 (84.71%) | 138 (79.77%) | ||
| Yes | 18 (10.53%) | 22 (12.87%) | 40 (23.26%) | 19 (11.11%) | 26 (15.29%) | 35 (20.23%) | ||
| 0.394 | 0.139 | |||||||
| 1 | 133 (77.77%) | 123 (71.93%) | 113 (65.69%) | 136 (79.53%) | 115 (67.65%) | 118 (68.21%) | ||
| 2 | 26 (15.20%) | 36 (21.05%) | 45 (26.16%) | 26 (15.20%) | 44 (25.88%) | 37 (21.39%) | ||
| 3 | 11 (6.43%) | 10 (5.85%) | 11 (6.40%) | 8 (4.68%) | 9 (5.29%) | 15 (8.67%) | ||
| 4 | 1 (0.58%) | 2 (1.17%) | 3 (1.74%) | 1 (0.58%) | 2 (1.17%) | 3 (1.73%) | ||
| BMI | 24.76 ± 3.53 | 25.83 ± 3.62 | 26.40 ± 3.68 | < 0.001 | 24.72 ± 3.64 | 25.85 ± 3.31 | 26.41 ± 3.84 | < 0.001 |
| Cl− | 102.33 ± 3.08 | 102.07 ± 3.17 | 102.72 ± 2.89 | 0.253 | 102.18 ± 3.08 | 102.42 ± 2.35 | 102.51 ± 3.58 | 0.496 |
| Creatinine | 67.42 ± 16.23 | 68.68 ± 24.28 | 69.93 ± 38.07 | 0.878 | 67.75 ± 17.27 | 68.50 ± 34.55 | 69.90 ± 29.47 | 0.788 |
| Cysteine protease inhibitor C | 1.05 ± 0.27 | 1.06 ± 0.30 | 1.15 ± 0.40 | 0.012 | 1.09 ± 0.27 | 1.09 ± 0.36 | 1.08 ± 0.37 | 0.563 |
| FT3 Free triiodothyrotropin | 4.61 ± 1.68 | 4.58 ± 0.78 | 4.93 ± 3.73 | 0.391 | 4.40 ± 0.96 | 5.05 ± 3.89 | 4.67 ± 1.27 | 0.039 |
| FT4 | 16.50 ± 4.44 | 15.88 ± 2.17 | 16.46 ± 4.80 | 0.710 | 15.87 ± 2.62 | 16.56 ± 4.77 | 16.31 ± 3.97 | 0.940 |
| TSH | 2.11 ± 1.73 | 2.64 ± 1.82 | 3.71 ± 8.84 | 0.003 | 2.35 ± 2.02 | 2.34 ± 1.49 | 3.80 ± 8.74 | 0.016 |
| HDL-C | 1.08 ± 0.30 | 1.09 ± 0.27 | 1.07 ± 0.25 | 0.561 | 1.10 ± 0.30 | 1.07 ± 0.27 | 1.08 ± 0.24 | 0.925 |
| LDL-C | 2.42 ± 0.77 | 2.52 ± 0.85 | 2.53 ± 0.86 | 0.538 | 2.57 ± 0.92 | 2.48 ± 0.77 | 2.42 ± 0.80 | 0.612 |
| Lipoprotein | 182.00 (92.00–325.00) | 169.50 (95.00–349.50) | 190.50 (96.50–344.25) | 0.848 | 218.00 (98.50–412.50) | 157.00 (91.75–320.00) | 165.00 (94.00–308.25) | 0.120 |
| K+ | 4.15 ± 0.42 | 4.22 ± 0.38 | 4.15 ± 0.44 | 0.226 | 4.18 ± 0.43 | 4.19 ± 0.43 | 4.16 ± 0.39 | 0.801 |
| LVEF | 55.66 ± 7.44 | 57.54 ± 5.35 | 57.90 ± 4.17 | 0.165 | 56.55 ± 6.56 | 57.24 ± 5.72 | 57.56 ± 4.91 | 0.632 |
| Na+ | 140.83 ± 2.84 | 141.23 ± 2.84 | 141.81 ± 2.39 | 0.017 | 140.98 ± 2.84 | 141.49 ± 2.55 | 141.44 ± 2.74 | 0.143 |
| TC | 4.12 ± 1.08 | 4.29 ± 1.10 | 4.40 ± 1.14 | 0.091 | 4.34 ± 1.25 | 4.27 ± 1.03 | 4.21 ± 1.05 | 0.942 |
| TG | 1.50 ± 0.91 | 1.53 ± 1.00 | 1.72 ± 1.12 | 0.141 | 1.52 ± 1.05 | 1.60 ± 1.04 | 1.63 ± 0.96 | 0.350 |
| UA | 288.93 ± 90.22 | 308.09 ± 71.10 | 298.71 ± 78.67 | 0.112 | 294.57 ± 90.00 | 291.34 ± 74.43 | 310.63 ± 74.28 | 0.036 |
| Urea | 5.28 ± 1.78 | 5.40 ± 1.64 | 5.55 ± 2.03 | 0.317 | 5.48 ± 1.80 | 5.42 ± 2.05 | 5.34 ± 1.60 | 0.814 |
| 0.178 | 0.584 | |||||||
| No | 109 (63.74%) | 110 (64.33%) | 124 (72.09%) | 110 (64.33%) | 118 (69.41%) | 115 (66.47%) | ||
| Yes | 62 (36.26%) | 61 (35.67%) | 48 (27.91%) | 61 (35.67%) | 52 (30.59%) | 58 (33.53%) | ||
| < 0.001 | < 0.001 | |||||||
| No | 159 (92.98%) | 143(83.63%) | 120 (69.77%) | 159 (92.98%) | 135 (79.41%) | 128 (73.99%) | ||
| Yes | 12 (7.02%) | 28 (16.37%) | 52 (30.23%) | 12 (7.02%) | 35 (20.59%) | 45 (26.01%) | ||
| 0.643 | 0.549 | |||||||
| No | 4(2.34%) | 1 (0.58%) | 3 (1.74%) | 4 (2.34%) | 3 (1.76%) | 1 (0.58%) | ||
| Yes | 167 (97.66%) | 170 (99.42%) | 169 (98.26%) | 167 (97.66%) | 167 (98.24%) | 172 (99.42%) | ||
| 0.019 | 0.921 | |||||||
| No | 24 (14.04%) | 37 (21.64%) | 44 (25.58%) | 37 (21.64%) | 33 (19.41%) | 35 (20.23%) | ||
| Yes | 147 (85.96%) | 134 (78.36%) | 128 (74.42%) | 134 (78.36%) | 137 (80.59%) | 138 (79.77%) | ||
| 0.043 | 0.321 | |||||||
| No | 83 (48.54%) | 70 (40.94%) | 60 (34.88%) | 79 (46.20%) | 65 (38.24%) | 69 (39.88%) | ||
| Yes | 88 (51.46%) | 101 (59.06%) | 112 (65.12%) | 92 (53.80%) | 105 (61.76%) | 104 (60.12%) | ||
| 0.587 | 0.265 | |||||||
| No | 71 (41.52%) | 75 (43.86%) | 66 (38.37%) | 70 (40.94%) | 63 (37.06%) | 79 (45.66%) | ||
| Yes | 100 (58.48%) | 96 (56.14%) | 106 (61.63%) | 101 (59.06%) | 107 (62.94%) | 94 (54.34%) | ||
| 0.007 | 0.035 | |||||||
| No | 10 (5.85%) | 2 (1.17%) | 1 (0.58%) | 9 (5.26%) | 1 (0.59%) | 3 (1.73%) | ||
| Yes | 161 (94.15%) | 169 (98.83%) | 171 (99.42%) | 162 (94.74%) | 169 (99.41%) | 170 (98.27%) | ||
| 0.029 | 0.363 | |||||||
| No | 95 (55.56%) | 107 (62.57%) | 119 (69.19%) | 100 (58.48%) | 109 (64.12%) | 112 (64.74%) | ||
| Yes | 76 (44.44%) | 64 (37.43%) | 53 (30.81%) | 71 (41.52%) | 61 (35.88%) | 61 (35.26%) | ||
| 0.577 | 0.574 | |||||||
| No | 144 (84.21%) | 137 (80.12%) | 139 (80.81%) | 142 (83.04%) | 141 (82.94%) | 137 (79.19%) | ||
| Yes | 27 (15.79%) | 34 (19.88%) | 33 (19.19%) | 29 (16.96%) | 29 (17.06%) | 36 (20.81%) | ||
Univariate analysis for MACE of PCI patients
| Covariate | Statistics | β (95%CI) | |
|---|---|---|---|
| Age | 61.92 ± 9.49 | 1.03 (1.01, 1.05) | 0.045 |
| Male | 345 (67.12%) | Reference | |
| Female | 169 (32.88%) | 0.88 (0.54, 1.45) | 0.625 |
| Nondrinker | 318 (61.87%) | Reference | |
| Current drinker | 161 (31.32%) | 0.94 (0.53, 1.66) | 0.832 |
| Quit | 35 (6.81%) | 0.54 (0.17, 1.66) | 0.281 |
| Nonsmoker | 262 (50.97%) | Reference | |
| Current smoker | 162 (31.52%) | 1.08 (0.58, 2.02) | 0.801 |
| Quit | 90 (17.51%) | 1.00 (0.48, 2.06) | 0.996 |
| Illiterate | 119 (23.15%) | Reference | |
| Primary school | 124 (24.12%) | 1.69 (0.85, 3.35) | 0.136 |
| Junior school | 144 (28.02%) | 1.07 (0.50, 2.29) | 0.868 |
| High school and above | 127 (24.71%) | 1.54 (0.72, 3.27) | 0.262 |
| No | 497 (96.69%) | Reference | |
| Yes | 17 (3.31%) | 0.48 (0.10, 2.21) | 0.346 |
| No | 371 (72.18%) | Reference | |
| Yes | 143 (27.82%) | 2.01 (1.82, 2.20) | 0.024 |
| No | 506 (98.44%) | Reference | |
| Yes | 8 (1.56%) | 0.64 (0.08, 5.32) | 0.675 |
| No | 208 (40.47%) | Reference | |
| Yes | 306 (59.53%) | 1.24(0.78,1.98) | 0.359 |
| No | 306 (59.53%) | Reference | |
| Yes | 208 (40.47%) | 0.90 (0.56, 1.46) | 0.677 |
| No | 481 (93.58%) | Reference | |
| Yes | 33 (6.42%) | 0.84 (0.31, 2.25) | 0.722 |
| No | 434 (84.44%) | Reference | |
| Yes | 80 (15.56%) | 1.85 (1.62, 2.08) | 0.038 |
| 1 | 369 (71.90%) | Reference | |
| 2 | 107 (20.82%) | 0.82 (0.46, 1.46) | 0.499 |
| 3 | 32 (6.23%) | 1.44 (0.62, 3.34) | 0.401 |
| 4 | 6 (1.17%) | 0.78 (0.09, 6.79) | 0.819 |
| BMI | 25.67 ± 3.66 | 1.03 (0.97, 1.10) | 0.384 |
| Cl− | 102.38 ± 3.05 | 1.00 (0.92, 1.08) | 0.957 |
| Creatinine | 68.73 ± 28.04 | 1.00 (0.99, 1.01) | 0.528 |
| Cysteine protease inhibitor C | 1.09 ± 0.34 | 1.19 (0.59, 2.39) | 0.632 |
| FT3 Free triiodothyrotropin | 4.71 ± 2.43 | 0.92 (0.71, 1.18) | 0.503 |
| FTH Free thyroxine | 16.25 ± 3.91 | 1.02 (0.95, 1.08) | 0.605 |
| TSH | 2.87 ± 5.46 | 0.99 (0.93, 1.06) | 0.756 |
| HDL-C | 1.08 ± 0.27 | 1.11 (0.43, 2.90) | 0.827 |
| LDL-C | 2.49 ± 0.83 | 0.80 (0.59, 1.10) | 0.178 |
| Lipoprotein | 179.00 (93.00–342.00) | 1.00 (1.00, 1.00) | 0.206 |
| K+ | 4.17 ± 0.41 | 0.77 (0.42, 1.41) | 0.396 |
| LVEF | 57.16 ± 5.70 | 0.97 (0.95, 0.99) | 0.036 |
| Na+ | 141.31 ± 2.71 | 0.97 (0.88, 1.06) | 0.466 |
| TC | 4.27 ± 1.11 | 0.92 (0.72, 1.17) | 0.495 |
| TG | 1.58 ± 1.02 | 1.08 (0.85, 1.37) | 0.513 |
| UA | 298.99 ± 80.09 | 1.00 (1.00, 1.00) | 0.294 |
| Urea | 5.41 ± 1.82 | 1.09 (0.96, 1.24) | 0.194 |
| No | 343 (66.73%) | Reference | |
| Yes | 171 (33.27%) | 0.95 (0.58, 1.55) | 0.834 |
| No | 422 (82.10%) | Reference | |
| Yes | 92 (17.90%) | 1.44 (0.84, 2.48) | 0.190 |
| No | 8 (1.56%) | Reference | |
| Yes | 506 (98.44%) | 1.10 (0.13, 9.39) | 0.934 |
| No | 105(20.43%) | Reference | |
| Yes | 409 (79.57%) | 1.45 (0.79, 2.68) | 0.232 |
| No | 213 (41.44%) | Reference | |
| Yes | 301 (58.56%) | 0.67 (0.42, 1.06) | 0.087 |
| No | 212 (41.25%) | Reference | |
| Yes | 302 (58.75%) | 1.08 (0.66, 1.75) | 0.756 |
| No | 13 (2.53%) | Reference | |
| Yes | 501 (97.47%) | 0.95 (0.20, 4.47) | 0.945 |
| No | 321 (62.45%) | Reference | |
| Yes | 193 (37.55%) | 1.41 (0.88, 2.25) | 0.155 |
Relationship between SBP and MACE in different models
| Variable | Crude model (model 1) | Adjust I (model 2) | Adjust II (model 3) |
|---|---|---|---|
| SBP (mmHg) | 1.01 (1.00, 1.03) 0.107 | 1.01 (1.00, 1.03) 0.125 | 1.01 (0.99, 1.03) 0.202 |
| 84–118 | Reference | Reference | Reference |
| 119–133 | 1.32 (0.76, 2.31) 0.324 | 1.37 (0.78, 2.40) 0.271 | 1.27 (0.65, 2.48) 0.481 |
| 134–168 | 1.36 (0.78, 2.37) 0.274 | 1.33 (0.76, 2.33) 0.314 | 1.37 (0.70, 2.68) 0.362 |
| 1.16 (0.88, 1.53) 0.279 | 1.15 (0.87, 1.51) 0.319 | 1.16 (0.83, 1.62) 0.374 |
All adjusted for age, sex, diabetes, cerebral infarction and LVEF
Relationship between DBP and MACE in different models
| Variable | Crude model (model 1) | Adjust I (model 2) | Adjust II (model 3) |
|---|---|---|---|
| DBP (mmHg) | 1.00 (0.98, 1.03) 0.867 | 1.01 (0.98, 1.03) 0.601 | 1.00 (0.97, 1.03) 0.977 |
| 53–70 | Reference | Reference | Reference |
| 71–79 | 1.01 (0.58, 1.76) 0.980 | 1.08 (0.61, 1.89) 0.800 | 0.83 (0.43, 1.61) 0.015 |
| 80–105 | 1.23 (0.72, 2.12) 0.442 | 1.35 (0.78, 2.34) 0.286 | 1.13 (0.60, 2.11) 0.713 |
| 1.11 (0.85, 1.46) 0.436 | 1.16 (0.88, 1.53) 0.282 | 1.08 (0.78, 1.48) 0 |
All adjusted for age, sex, diabetes, cerebral infarction and LVEF
Fig. 2Association between systolic blood pressure and the occurrence of MACE
Fig. 3Association between diastolic blood pressure and the occurrence of MACE
Results of SBP and MACE using two piecewise linear regression
| Inflection point of platelets | Effect size | 95% CI | |
|---|---|---|---|
| < 121 | 1.09 | 1.01–1.18 | 0.029 |
| ≥ 121 | 1.00 | 0.98–1.02 | 0.820 |